Study: NCT03383783

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F (placebo, negative control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 500 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 500 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 500 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 500 ppm F as NaF (dose-response control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as NaF (positive control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as NaF (positive control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as NaF (positive control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.

Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm F as NaF (positive control)
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.